NO20045529L - Substituerte heterocykliske derivater hvilke er anvendelige som antidiabetes- og antiovervektsmidler og metode - Google Patents

Substituerte heterocykliske derivater hvilke er anvendelige som antidiabetes- og antiovervektsmidler og metode

Info

Publication number
NO20045529L
NO20045529L NO20045529A NO20045529A NO20045529L NO 20045529 L NO20045529 L NO 20045529L NO 20045529 A NO20045529 A NO 20045529A NO 20045529 A NO20045529 A NO 20045529A NO 20045529 L NO20045529 L NO 20045529L
Authority
NO
Norway
Prior art keywords
diabetic
substituted heterocyclic
derivatives useful
obesity agents
heterocyclic derivatives
Prior art date
Application number
NO20045529A
Other languages
English (en)
Other versions
NO329328B1 (no
Inventor
Charles Z Ding
Sean Chen
Peter T Cheng
Timothy F Herpin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20045529L publication Critical patent/NO20045529L/no
Publication of NO329328B1 publication Critical patent/NO329328B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20045529A 2002-07-09 2004-12-17 Substituerte, heterocykliske derivater, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom NO329328B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39455302P 2002-07-09 2002-07-09
PCT/US2003/021331 WO2004004655A2 (en) 2002-07-09 2003-07-08 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method

Publications (2)

Publication Number Publication Date
NO20045529L true NO20045529L (no) 2005-02-03
NO329328B1 NO329328B1 (no) 2010-09-27

Family

ID=30115733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045529A NO329328B1 (no) 2002-07-09 2004-12-17 Substituerte, heterocykliske derivater, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom

Country Status (23)

Country Link
US (2) US6875782B2 (no)
EP (1) EP1531810B1 (no)
JP (1) JP4541883B2 (no)
KR (1) KR101120337B1 (no)
CN (1) CN1665500A (no)
AT (1) ATE543497T1 (no)
AU (1) AU2003248861B2 (no)
BR (1) BR0312503A (no)
CA (1) CA2490972C (no)
ES (1) ES2380319T3 (no)
GE (1) GEP20084475B (no)
HR (1) HRP20050001A2 (no)
IL (1) IL165809A (no)
IS (1) IS7629A (no)
MX (1) MXPA05000279A (no)
NO (1) NO329328B1 (no)
NZ (1) NZ537251A (no)
PL (1) PL375230A1 (no)
RS (1) RS20050002A (no)
RU (1) RU2325381C2 (no)
UA (1) UA79296C2 (no)
WO (1) WO2004004655A2 (no)
ZA (1) ZA200500029B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012733A2 (en) * 2002-08-01 2004-02-12 Neurosearch A/S Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20060183897A1 (en) * 2003-03-18 2006-08-17 Chakravarty Prasun K Biaryl substituted triazoles as sodium channel blockers
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
FR2861301B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861300B1 (fr) * 2003-10-24 2008-07-11 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
FR2861302A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
WO2006032042A2 (en) * 2004-09-15 2006-03-23 Regeneron Pharmaceuticals, Inc. Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
EP1866298A2 (en) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006117743A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Substituted aromatic compounds as antidiabetic agents
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
FR2889191A1 (fr) * 2005-07-28 2007-02-02 Cerep Sa Composes derives de 5-benzylidene imidazolidine 2,4-dione et leur utilisation en tant qu'antagonistes de mchr-1
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
EP1951220A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
JP2009538892A (ja) * 2006-05-30 2009-11-12 アストラゼネカ アクチボラグ アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸
WO2007138304A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors
US20080009534A1 (en) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CA2673290A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN103694195B (zh) * 2013-09-18 2016-04-06 华东师范大学 芳香杂环类小分子有机化合物及衍生物、制备方法及医药用途
EP3190103A1 (en) * 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibitors of the pd-1/pd-l1 protein/protein interaction
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
KR102131359B1 (ko) * 2018-09-07 2020-07-07 오토텔릭바이오 주식회사 안정성이 향상된 의약 조성물
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018130A1 (en) 1993-12-28 1995-07-06 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine and benzothiazepine derivatives
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
WO1997000258A1 (en) 1995-06-15 1997-01-03 Meiji Seika Kabushiki Kaisha Tricyclic benzazepine compounds
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) * 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
JPH1067759A (ja) 1996-06-20 1998-03-10 Sankyo Co Ltd 除草性アゾール誘導体
JPH11263775A (ja) 1997-09-08 1999-09-28 Sankyo Co Ltd ヒドロキシアニリン誘導体
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
FR2778314B1 (fr) 1998-05-07 2002-06-14 Rhone Poulenc Agrochimie Composition fongicide synergique comprenant un compose analogue de la strobilurine
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6506781B1 (en) 1999-09-08 2003-01-14 Smithkline Beecham Corporation Oxazole PPAR antagonist
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) * 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
HK1045991B (en) 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
BR0312503A (pt) 2007-06-26
IS7629A (is) 2005-01-05
US20050119312A1 (en) 2005-06-02
CA2490972C (en) 2012-05-29
UA79296C2 (en) 2007-06-11
MXPA05000279A (es) 2005-03-31
HRP20050001A2 (en) 2005-08-31
JP2006501187A (ja) 2006-01-12
CN1665500A (zh) 2005-09-07
ATE543497T1 (de) 2012-02-15
IL165809A (en) 2010-05-17
AU2003248861B2 (en) 2009-01-22
KR20050025951A (ko) 2005-03-14
EP1531810A2 (en) 2005-05-25
NZ537251A (en) 2007-02-23
RU2325381C2 (ru) 2008-05-27
KR101120337B1 (ko) 2012-02-29
AU2003248861A1 (en) 2004-01-23
GEP20084475B (en) 2008-09-10
US6875782B2 (en) 2005-04-05
RU2005103395A (ru) 2005-08-10
CA2490972A1 (en) 2004-01-15
WO2004004655A2 (en) 2004-01-15
WO2004004655A3 (en) 2004-10-14
ZA200500029B (en) 2006-06-28
RS20050002A (sr) 2007-09-21
IL165809A0 (en) 2006-01-15
NO329328B1 (no) 2010-09-27
EP1531810A4 (en) 2008-05-28
ES2380319T3 (es) 2012-05-10
US20040063762A1 (en) 2004-04-01
EP1531810B1 (en) 2012-02-01
US7507757B2 (en) 2009-03-24
JP4541883B2 (ja) 2010-09-08
PL375230A1 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20045529L (no) Substituerte heterocykliske derivater hvilke er anvendelige som antidiabetes- og antiovervektsmidler og metode
NO20034661L (no) Nociceptin-analoger
WO2004004665A3 (en) Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
NO20034660D0 (no) Spiropyrazolforbindelser
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
NO20065178L (no) Tienopyridinderivater
CY1110000T1 (el) Ενωσεις οκταϋδροβενζιμιδαζολονης ως αναλγητικα
DK1499577T3 (da) 2-(2,6-dichlorphenyl)-diarylimidazoler
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
BR0317715A (pt) Composições e processos de uso de collajolie
FI20040391A0 (fi) Hakeosasten esikäsittely suurkuiduttamalla
DE60215683D1 (de) Uhrgehäuse
CY1114692T1 (el) Εστερες στη θεση 20 των καμπτοθεκινων
MXPA03009602A (es) Analogos de nociceptina.
ITBO20020068A0 (it) Unita' per l'alimentazione di componenti ad una stazione di montaggiodi almeno un componente su un pannello di legno o simili
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
DK1569634T3 (da) Anvendelse af en PPAR-agonist og metformin til behandling af fedme
DK1532141T3 (da) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazol-derivater og anvendelse deraf som antidepressiv
DK1188815T3 (da) Transparent, elastisk og fritstående forbindelse til fremstillingen af lys og fritstående lys opnået med denne forbindelse
HRP20050611B1 (hr) Kombinacijski lijek
ITMI20020624A1 (it) Composizioni ad attivita' biostimolante
NO20001751L (no) Nye forbindelser til bruk som neuroprotektive midler
DE50211891D1 (de) Härtbare cyanat-zusammensetzungen
FR2838790B1 (fr) Pompe
EA200000946A1 (ru) Кристаллическая форма пароксетина

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees